Germany's Vaccine Commission Recommends Novavax's COVID-19 Vaccine For Adults: Reuters

Germany's expert panel on vaccine use has recommended Novavax Inc's NVAX protein-based COVID-19 vaccine for primary immunization for people over 18 years.

  • The advisory group known as STIKO said a booster shot should still be given with an mRNA vaccine, reported Reuters.
  • mRNA technology is behind the two most commonly used COVID-19 vaccines from - Pfizer Inc PFEBioNTech SE BNTX and Moderna Inc MRNA.
  • Novavax's COVID-19 vaccine NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2. It is formulated with an adjuvant to enhance the immune response and stimulate high neutralizing antibodies.
  • Germany expects to receive 3.8 million doses of Novavax's Nuvaxovid vaccine by March 20 and a total of 34 million this year.
  • STIKO also updated its general recommendation for booster shots and now advises at-risk groups, including those aged 70 and over. Health workers to get a second booster, or a fourth shot overall, against COVID-19 with an mRNA vaccine.
  • Novavax also received provisional approval from New Zealand's medicines regulator for its COVID-19 vaccine, Nuvaxovid, for individuals 18 years of age and older.
  • Novavax and the New Zealand Government previously announced an advance purchase agreement for 10.7 million Novavax's COVID-19 vaccine doses.
  • Yesterday, Britain's regulatory agency gave conditional approval to Novavax's COVID-19 vaccine.
  • Price Action: NVAX shares are trading 3.59% higher at $91.67 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccinewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!